<HashMap><database>GEO</database><file_versions><headers><Content-Type>application/xml</Content-Type></headers><body><files><Other>ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE327nnn/GSE327133/</Other></files><type>primary</type></body><statusCode>OK</statusCode><statusCodeValue>200</statusCodeValue></file_versions><scores/><additional><omics_type>Transcriptomics</omics_type><species>Homo sapiens</species><gds_type>Expression profiling by high throughput sequencing</gds_type><full_dataset_link>https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE327133</full_dataset_link><repository>GEO</repository><entry_type>GSE</entry_type></additional><is_claimable>false</is_claimable><name>Virus-like particles enable targeted gene engineering and pooled CRISPR screening in primary human myeloid cells [CRISPRoff]</name><description>Primary human myeloid cells are promising candidates for immunotherapy, yet efficient and scalable technologies for genetic engineering and screening in these cells are limited. Here we present a virus-like particle (VLP)-based toolkit that delivers diverse CRISPR genome editing modalities to human monocytes, macrophages, and dendritic cells with high efficiency while preserving viability and innate immune responsiveness. VLP-mediated delivery of ribonucleoprotein payloads supports gene knockout, base editing, and epigenetic silencing. Furthermore, in combination with AAV-mediated donor delivery, this approach enables site-specific integration of large DNA sequences via homology-directed repair. We also developed SLICeVLP, a system combining sgRNA delivery via VPX-lentivirus with Cas9 protein delivery via engineered virus-like particles (eVLPs), and applied it to perform pooled loss-of-function screens and Perturb-seq in human macrophages. We uncovered regulators of TNF production and CD80 expression in human macrophages, converging on TNFAIP3 as a central regulator of inflammatory polarization. TNFAIP3 ablation promoted a pro-inflammatory cell state that is resistant to suppressive polarization, and augmented cytotoxicity in engineered HER2 CAR-macrophages. Taken together, this platform enables unbiased functional genomics in primary human myeloid cells, with direct implications for myeloid cell therapy design.</description><dates><publication>2026/04/08</publication></dates><accession>GSE327133</accession><cross_references><GSM>GSM9649095</GSM><GSM>GSM9649073</GSM><GSM>GSM9649094</GSM><GSM>GSM9649072</GSM><GSM>GSM9649075</GSM><GSM>GSM9649074</GSM><GSM>GSM9649077</GSM><GSM>GSM9649076</GSM><GSM>GSM9649079</GSM><GSM>GSM9649078</GSM><GSM>GSM9649091</GSM><GSM>GSM9649090</GSM><GSM>GSM9649071</GSM><GSM>GSM9649093</GSM><GSM>GSM9649092</GSM><GSM>GSM9649070</GSM><GSM>GSM9649084</GSM><GSM>GSM9649083</GSM><GSM>GSM9649086</GSM><GSM>GSM9649085</GSM><GSM>GSM9649088</GSM><GSM>GSM9649087</GSM><GSM>GSM9649068</GSM><GSM>GSM9649089</GSM><GSM>GSM9649080</GSM><GSM>GSM9649082</GSM><GSM>GSM9649081</GSM><GSM>GSM9649069</GSM><GPL>34284</GPL><GSE>327133</GSE><taxon>Homo sapiens</taxon></cross_references></HashMap>